邓觅
人物履历
2007–2012 美国内布拉斯加大学医学中心 博士
2012–2015 美国得克萨斯大学西南医学中心 博士后
2015–2017 美国得克萨斯大学西南医学中心 讲师
2017–2020 美国得克萨斯大学西南医学中心 助理教授
学术任职
2020–现在 北京大学国际癌症研究院/北京大学肿瘤医院 研究员
2018–现在 Antibody Therapeutics 期刊编委/助理编辑
2020–现在 Translational Oncology 期刊编委
2021–现在 Frontiers in Immunology 期刊主题编辑
2021–现在 中华医学会肿瘤学分会 第十二届委员会青年学组成员
2021–现在 中国病理生理学会第九届实验血液学专业委员会血液免疫学组委员
2021–现在 中国人体健康科技促进会 淋巴瘤专业委员会常务委员
研究方向
我们长期以肿瘤免疫学为研究方向，主要以免疫细胞和肿瘤细胞为研究对象，致力于探索肿瘤细胞逃逸免疫监控的分子机制，利用细胞生物学、高通量多组学等方法和人源化动物模型，发现新的肿瘤免疫治疗靶点，开发大分子抗体药物和细胞治疗技术。
1）探索肿瘤免疫微环境中免疫细胞与其他细胞之间的相互作用关系；
2）阐述免疫检查点在肿瘤免疫微环境中的生物学功能和分子机制；
3）开发重大疾病的免疫治疗的新药物和新方法。
学术成果
论文
1. Yang T; Qian Y; Liang X, Wu J, Zou M, Deng M. (2022) LILRB4, an immune checkpoint on myeloid cells. Blood Sci . 4(2): 49-56.
2. Wu G, Xu Y, Schultz R, Chen H, Xie J, Deng M, Liu X, Gui X, John S, Lu Z, Arase H, Zhang N, An Z, Zhang CC. (2021) LILRB3 supports acute myeloid leukemia development and regulates T cell anti-tumor immune responses through the TRAF2-cFLIP-NF-kB signaling axis. Nat Cancer. 2:1170-84.
3. Gu Z, Liu Y, Zhang Y, Cao H, Lyu J, Wang X, Wylie A, Newkirk S, Jones A, Lee M, Botten G, Deng M, Dickerson K, Zhang CC, An W, Abrams J, Xu J. (2021) Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia. Nat Genet. 53(5):672-82.
4. Deng M, Chen H, Liu X, Huang R, He Y, Yoo B, Xie J, John S, Zhang N, An Z, Zhang CC. (2021) Leukocyte immunoglobulin-like receptor subfamily B (LILRB): therapeutic targets in cancer. Antib Ther . 4(1):16-33.
5. Anami Y, Deng M, Gui X, Yamaguchi A, Yamazaki C, Zhang N, Zhang CC, An Z, and Tsuchikama K. (2020) LILRB4-Targeting Antibody–Drug Conjugates for the Treatment of Acute Myeloid Leukemia. Mol Cancer Ther. 19：2330-2339.
6. Li Z, Deng M, Huang F, Jin C, Sun S, Chen H, Liu X, He L, Sadek AH, Zhang CC. (2020) LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 17(3):272-282.
7. Gui X, Deng M, Song H, Chen Y, Xie J, Li Z, He L, Huang F, Xu Y, Anami Y, Yu H, Yu C, Li L, Yuan Z, Xu X, Wang Q, Chai Y, Huang T, Shi Y, Tsuchikama K, Liao XC, Xia N, Gao GF, Zhang N, Zhang CC, An Z. (2019) Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T cell suppression and blocks AML development. Cancer Immunol Res. 7(8):1244-57.
8. Deng M. (2019) The approval of Sinitilimab for classical Hodgkin’s lymphoma: Views and Perspectives of anti-PD-1/PD-L1 antibodies in China. Antib Ther . 2(2): 54-55.
9. Deng M, Gui X, Kim J*, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen G-Q, Fu Y-X, Liao XC, An Z, Zheng J, Zhang N, Zhang CC. (2018) LILRB4 signalling in leukaemia cells mediates T cell suppression and tumor infiltration. Nature . 562(7728):605-9.
10. John S, Chen H, Deng M, Gui X, Wu G, Chen W, Li Z, Zhang N, An Z, Zhang CC. (2018) A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther . 26(10):2487-95.
11. Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, Han X, Xie F, Tyner JW, Coligan JE, Collins RH, Xiao X, You MJ, Zhang CC. (2015) The ITIM-containing receptor LAIR1 is essential for acute myeloid leukemia development. Nat Cell Biol . 17(5):665-77.
12. Deng M, Lu Z, Zheng J, Wan X, Chen X, Hirayasu K, Sun H, Lam Y, Chen L, Wang Q, Song C, Huang N, Gao GF, Jiang Y, Arase H, Zhang CC. (2014) A motif in LILRB2 critical for ANGPTL2 binding and activation. Blood . 124(6):924-35.
13. Yu X, Wang Y, Deng M, Li Y, Ruhn KA, Zhang CC, Hooper LV. (2014) The basic leucine zipper transcription factor NFIL3 directs the development of a common innate lymphoid cell precursor. Elife . 3. doi: 10.7554/eLife.04406.
14. Yan Q, Gong L, Deng M, Zhang L, Sun S, Liu J, Ma H-L, Yuan D, Chen P-C, Hu X-H, Liu J-P, Qin J, Xiao L, Huang X-Q, Zhang J, Li DW-C. (2010). Sumoylation activates the transcriptional activity of p32 Pax-6, an important transcription factor for eye and brain development. Proc Natl Acad Sci USA. 107(49): 21034-39.
15. Deng M, Chen PC, Xie S, Zhao J, Gong L, Liu J, Zhang L, Sun S, Liu J, Ma H, Batra S, Li DW. (2010). The small heal shock protein alphaA-crystallin is expressed in pancreas and acts as negative regulator of carcinogenesis. Biochim Biophys Acta - Mol Basis Dis . 1802: 621-31.
16. Xiao L, Gong L, Yuan D, Deng M, Chen L, Zhang L, Yan Q, Liu J-P, Hu X, Sun S, Liu J, Ma H, Zheng C, Fu H, Chen P, Zhao J, Xie S, Zeng X, Zou L, Xiao Y-M, Liu W-B, Zhang J, Liu Y and Li D W-C. (2010). Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation . Cell Death & Differ . 17(9): 1448-62.
专利
1. Zhang CC, Deng M, An Z, Xiong W, Zhang N, Zheng, J. (2016) Anti-lilrb Antibodies and their use in detecting and treating cancer. (Patent number: PCT/US2016/020838)
2. Bernstein ID, Zhang CC, Deng M, Lu Z, Zheng J. (2017) Lilrb2 and notch-mediated expansion of hematopoietic precursor cells. (Patent number: PCT/US2015/031959)
3. Zhang CC, Liu Y, Zheng J, Deng M, Chen C, Liu J. (2017) Novel compounds supports hematopoietic stem cells and red blood cells. (Patent number: PCT/US2015/030352)
4. Zhang CC, An Z, Zhang N, Deng M, Kim, J, Gui X. (2018) Methods for identifying lilrb-blocking antibodies. (Patent number: PCT/US2017/044171)
5. Liao X, Liu Q, An Z, Zhang N, Gui X, Zhang CC, Deng M, Xie J. (2018) Anti-lair1 antibodies and their uses. (Patent number: PCT/US2018/012040)
6. Zhang CC, John S, Chen H, Deng M, Gui X, Zhang N, An Z. (2019) Targeting LILRB4 with CAR-T or CAR-NK cells in the treatment of cancer. (Patent number: PCT/US2018/059362)
7. An Z, Zhang CC, Zhang N, Gui X, Deng M, Huang T, Liu Q, Liao X. (2020) Novel LILRB4 antibodies and uses thereof. (Patent number: PCT/US2019/050727)
8. Zhang CC, Zhang N, An Z, Wu G, Kim J, Chen H, Deng M, Huang R. (2021) Antibodies against LILRB3 for therapeutic and diagnostic uses. (Patent number: PCT/US2021/061630)[1]